Haemonetics' $357.8 million in second-quarter revenue exceeded the $345.1 million estimate, and Barrington raised its target while keeping its Outperform rating. These reports support a positive read, with no company setback reported in the story.
The sales result gives Barrington a company-specific reason for its higher target. The story reports no company setback, though it offers only one sales measure and an analyst's view.
Follow Haemonetics Corporation (HAE) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for HAE